CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $918,486, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
90.89BINR947.13M · vs all stocks (USD)
Revenue (TTM)
88.14MINR918.49K · vs all stocks (USD)
Beta
0.8370xvs all stocks
52-Week Change
62.04%vs all stocks
Market Capitalization
90.89BINR947.13M · vs all stocks (USD)
Enterprise Value
79.81BINR831.72M · vs all stocks (USD)
Forward P/E
16.62xPrice to Book (MRQ)
14.34xEnterprise to Revenue
905.53xEnterprise to EBITDA
-21.74xGross Margin
100.00%Operating Margin
-3776.37%Return on Assets (TTM)
-44.27%Return on Equity (TTM)
-46.73%Revenue (TTM)
88.14MINR918.49K · vs all stocks (USD)
Revenue per Share (TTM)
0.3690INRUpdated Sep 29, 2026Quarterly Revenue Growth
91.00%Gross Profit (TTM)
81.82MINR852.65K · vs all stocks (USD)
EBITDA (TTM)
-3.67BINR-38.25M · vs all stocks (USD)
Net Income (TTM)
-3.52BINR-36.73M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
91.02%Operating Cash Flow (TTM)
-3.01BINR-31.41M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-2.76BINR-28.80M · vs all stocks (USD)
5-Year Average Dividend Yield
0.69%vs all stocks
Payout Ratio
0.00%Revenue
71.15MINRFY2026 · Mar 31, 2026Cost of Goods Sold
0.00INRFY2026 · Mar 31, 2026Gross Profit
71.15MINRFY2026 · Mar 31, 2026Operating Income
-2.90BINR-30.23M · vs all stocks (USD)
Pre-tax Income
-2.76BINRFY2026 · Mar 31, 2026Income Tax Expense
0.00INRFY2026 · Mar 31, 2026Net Income
-2.76BINRFY2026 · Mar 31, 2026EBIT
-2.76BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
-2.71BINRFY2026 · Mar 31, 2026Research & Development
2.48BINRFY2026 · Mar 31, 2026Other Operating Expenses
192.80MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
1.58MINRFY2026 · Mar 31, 2026EPS (Basic)
-12.13INRFY2026 · Mar 31, 2026EPS (Diluted)
-12.13INRFY2026 · Mar 31, 2026Basic Shares Outstanding
227.82MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
227.82MSharesFY2026 · Mar 31, 2026Net Income from Continuing Operations
-2.76BINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
-2.97BINRFY2026 · Mar 31, 2026Free Cash Flow
-3.02BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
82.79MINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
-2.76BINRFY2026 · Mar 31, 2026Stock-based Compensation
17.87MINRFY2026 · Mar 31, 2026Other Non-cash Items
-44.63MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-1.72MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-173.67MINRFY2026 · Mar 31, 2026Capital Expenditures
-50.83MINRFY2026 · Mar 31, 2026Other Investing Activity
-9.62MINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-60.45MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
7.57BINRFY2026 · Mar 31, 2026Shares Outstanding
282.56MSharesUpdated Sep 29, 2026Float Shares
87.59MSharesUpdated Sep 29, 2026% Held by Insiders
66.57%vs all stocks
% Held by Institutions
2.88%vs all stocks
Total Cash (MRQ)
5.18BINR53.99M · vs all stocks (USD)
Total Cash per Share (MRQ)
19.65INRUpdated Sep 29, 2026Total Debt (MRQ)
166.94MINR1.74M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0282xCurrent Ratio (MRQ)
29.15xBook Value per Share (MRQ)
22.43INRUpdated Sep 29, 2026Total Assets
6.24BINR65.05M · vs all stocks (USD)
Total Current Assets
5.47BINRFY2026 · Mar 31, 2026Total Liabilities
328.14MINRFY2026 · Mar 31, 2026Total Non-current Assets
775.05MINRFY2026 · Mar 31, 2026Total Non-current Liabilities
19.17MINRFY2026 · Mar 31, 2026Total Current Liabilities
308.97MINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
82.79MINRFY2026 · Mar 31, 2026Other Short-term Investments
5.14BINRFY2026 · Mar 31, 2026Accounts Receivable
15.08MINRFY2026 · Mar 31, 2026Inventory
1.02MINRFY2026 · Mar 31, 2026Accounts Payable
48.13MINRFY2026 · Mar 31, 2026Short-term Debt
166.94MINRFY2026 · Mar 31, 2026Other Current Liabilities
22.26MINRFY2026 · Mar 31, 2026Common Stock (Book)
263.72MINRFY2026 · Mar 31, 2026Total Shareholders' Equity
5.91BINR61.63M · vs all stocks (USD)
52-Week Low
124.11INRUpdated Sep 29, 202652-Week High
403.35INRUpdated Sep 29, 202652-Week Change
62.04%vs all stocks
Beta
0.8370xvs all stocks
50-Day MA
342.44INRUpdated Sep 29, 2026200-Day MA
235.74INRUpdated Sep 29, 2026Avg 10-Day Volume
399.22KSharesUpdated Sep 29, 2026Avg 30-Day Volume
749.50KSharesUpdated Sep 29, 2026Diluted EPS (TTM)
-14.61INRUpdated Sep 29, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.62
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $918,486, lower than 95% of all stocks globallySignificant
Revenue (USD): 918,486.098Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Tong Ren Tang Chinese Medicine Company Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharma Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bioventus Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cullinan Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
KPC Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Green Cross Corporation
Tier 1ProductionApproval-Gated PipelineRule
Kura Oncology Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Arbutus Biopharma Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hangzhou Biotest Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Medincell SA
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Surrozen, Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Fastly Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Kneat.com Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC